Abstract Details

Title Neurologic and Psychiatric Comorbidities Associated with Drug-Resistant Epilepsy

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P7 - Poster Session 7 (5:00 PM-6:00 PM)

Poster/Presentation
Number 9-016

Objective This study re-evaluates the prevalence of DRE, its correlation with comorbid neurological and psychiatric conditions, and identifies factors predictive of seizure control.

Background About one-third of persons with epilepsy develop drug-resistant epilepsy (DRE).

Design/Methods This cross-sectional study conducted in a level 3 epilepsy center. DRE, defined as failure to achieve seizure control after adequate trials of two antiseizure medications, was compared with seizure-free patients (seizure-free >6 months).

Results Of 613 patients, 188 (30.6%) had DRE, while 425 (69.3%) were seizure-free. The mean ages were 40 years in the DRE group and 43 years in the seizure-free group. The mean age at seizure onset was 22.3 years in the DRE group and 24.5 years in the seizure-free group. Mean disease duration was similar, at 17.7 years for DRE patients and 18.5 years for seizure-free patients. Focal epilepsy was more common in the DRE group (61.2%) compared to the seizure-free group (24%) (p < 0.0001). Generalized epilepsy was more prevalent in the seizure-free group (40%) than in the DRE group (30.9%) (p = 0.16). ADHD was reported in 12% of DRE patients and 9.1% of seizure-free patients (p = 0.25). Major depression was less prevalent in the DRE group (10.1%) compared to the seizure-free group (25.8%) (p < 0.0001). Generalized anxiety disorder (GAD) was found in 20% of DRE patients and 24% of seizure-free patients (p = 0.30). Developmental disability and learning disability (DD/LD) were more prevalent in DRE patients (29.2% and 29.7%) compared to the seizure-free group (15.2% each) (p < 0.0001). Autism was found in 8.5% of DRE patients and 5.8% of seizure-free patients (p = 0.20).

Conclusions DD/LD is significantly more common in DRE patients, with higher rates of ADHD, GAD, and autism. These findings suggest the need for targeted interventions to improve outcomes for these patients.

Authors/Disclosures
Hira Pervez, MD, MBBS (University of Toledo) PRESENTER	Dr. Pervez has nothing to disclose.
Fahham Asghar, MD (The University of Toledo)	Mr. Asghar has nothing to disclose.
Gulbudin Muhammad, MD	Dr. Muhammad has nothing to disclose.
Syed Owais, MD	Dr. Owais has nothing to disclose.
Anum H. Riaz, MD	Dr. Riaz has nothing to disclose.
Naeem Mahfooz, MD	Dr. Mahfooz has nothing to disclose.
Ajaz Sheikh, MD (ProMedica Neurosciences Center)	Dr. Sheikh has nothing to disclose.
Imran I. Ali, MD, FAAN (University of Toledo COM)	Dr. Ali has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for ABPN.

��ɫ��

��ɫ��